
Shares of medical device maker Medtronic MDT.N rise 3% to $92.16 premarket
Late on Thursday, the Centers for Medicare & Medicaid Services released a memosupporting insurance coverage for renal denervation (RDN) procedures, which are used to treat high blood pressure
Brokerage BTIG says this is a "win" for Medtronic who has been preparing hospitals for coverage with the launch of its Symplicity Spyral renal denervation device
"We came away encouraged by the proposed coverage for a broader patient population" says brokerage Leerink Partners
RBC Capitals Markets says this indicates MDT's potential to tap into the vast market, giving them further confidence in the durability of co's revenue growth profile
Up to last close, stock was up 12% YTD